Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 230

1.

Genomic analysis using high-density single nucleotide polymorphism-based oligonucleotide arrays and multiplex ligation-dependent probe amplification provides a comprehensive analysis of INI1/SMARCB1 in malignant rhabdoid tumors.

Jackson EM, Sievert AJ, Gai X, Hakonarson H, Judkins AR, Tooke L, Perin JC, Xie H, Shaikh TH, Biegel JA.

Clin Cancer Res. 2009 Mar 15;15(6):1923-30. doi: 10.1158/1078-0432.CCR-08-2091. Epub 2009 Mar 10.

2.

High-resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumors.

Hasselblatt M, Isken S, Linge A, Eikmeier K, Jeibmann A, Oyen F, Nagel I, Richter J, Bartelheim K, Kordes U, Schneppenheim R, Frühwald M, Siebert R, Paulus W.

Genes Chromosomes Cancer. 2013 Feb;52(2):185-90. doi: 10.1002/gcc.22018. Epub 2012 Oct 17.

PMID:
23074045
3.

High-density single nucleotide polymorphism array analysis in patients with germline deletions of 22q11.2 and malignant rhabdoid tumor.

Jackson EM, Shaikh TH, Gururangan S, Jones MC, Malkin D, Nikkel SM, Zuppan CW, Wainwright LM, Zhang F, Biegel JA.

Hum Genet. 2007 Sep;122(2):117-27. Epub 2007 May 31.

PMID:
17541642
4.

Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors.

Eaton KW, Tooke LS, Wainwright LM, Judkins AR, Biegel JA.

Pediatr Blood Cancer. 2011 Jan;56(1):7-15. doi: 10.1002/pbc.22831.

5.

Genome-wide approach to identify second gene targets for malignant rhabdoid tumors using high-density oligonucleotide microarrays.

Takita J, Chen Y, Kato M, Ohki K, Sato Y, Ohta S, Sugita K, Nishimura R, Hoshino N, Seki M, Sanada M, Oka A, Hayashi Y, Ogawa S.

Cancer Sci. 2014 Mar;105(3):258-64. doi: 10.1111/cas.12352. Epub 2014 Feb 26.

6.

Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors.

Biegel JA, Tan L, Zhang F, Wainwright L, Russo P, Rorke LB.

Clin Cancer Res. 2002 Nov;8(11):3461-7.

7.
8.

SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas.

Modena P, Lualdi E, Facchinetti F, Galli L, Teixeira MR, Pilotti S, Sozzi G.

Cancer Res. 2005 May 15;65(10):4012-9.

9.

Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations.

Sévenet N, Lellouch-Tubiana A, Schofield D, Hoang-Xuan K, Gessler M, Birnbaum D, Jeanpierre C, Jouvet A, Delattre O.

Hum Mol Genet. 1999 Dec;8(13):2359-68.

PMID:
10556283
10.

Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma: a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor.

Kohashi K, Izumi T, Oda Y, Yamamoto H, Tamiya S, Taguchi T, Iwamoto Y, Hasegawa T, Tsuneyoshi M.

Hum Pathol. 2009 Mar;40(3):349-55. doi: 10.1016/j.humpath.2008.08.007. Epub 2008 Oct 29.

PMID:
18973917
11.

hSNF5/INI1 inactivation is mainly associated with homozygous deletions and mitotic recombinations in rhabdoid tumors.

Rousseau-Merck MF, Versteege I, Legrand I, Couturier J, Mairal A, Delattre O, Aurias A.

Cancer Res. 1999 Jul 1;59(13):3152-6.

12.

Mutation of the INI1 gene in composite rhabdoid tumor of the endometrium.

Donner LR, Wainwright LM, Zhang F, Biegel JA.

Hum Pathol. 2007 Jun;38(6):935-9. Epub 2007 Mar 21.

13.

Non-linkage of familial rhabdoid tumors to SMARCB1 implies a second locus for the rhabdoid tumor predisposition syndrome.

Frühwald MC, Hasselblatt M, Wirth S, Köhler G, Schneppenheim R, Subero JI, Siebert R, Kordes U, Jürgens H, Vormoor J.

Pediatr Blood Cancer. 2006 Sep;47(3):273-8.

PMID:
16206192
14.

SMARCB1 deletion by a complex three-way chromosomal translocation in an extrarenal malignant rhabdoid tumor.

Bahrami A, Lee S, Caradine KD, Raimondi SC, Folpe AL.

Cancer Genet. 2014 Sep;207(9):437-40. doi: 10.1016/j.cancergen.2014.08.002. Epub 2014 Aug 24.

PMID:
25312828
15.

Cyclin D1 is overexpressed in atypical teratoid/rhabdoid tumor with hSNF5/INI1 gene inactivation.

Fujisawa H, Misaki K, Takabatake Y, Hasegawa M, Yamashita J.

J Neurooncol. 2005 Jun;73(2):117-24.

PMID:
15981100
16.

Chromosome mechanisms and INI1 inactivation in human and mouse rhabdoid tumors.

Rousseau-Merck MF, Fiette L, Klochendler-Yeivin A, Delattre O, Aurias A.

Cancer Genet Cytogenet. 2005 Mar;157(2):127-33.

PMID:
15721633
17.

Aberrations of the hSNF5/INI1 gene are restricted to malignant rhabdoid tumors or atypical teratoid/rhabdoid tumors in pediatric solid tumors.

Uno K, Takita J, Yokomori K, Tanaka Y, Ohta S, Shimada H, Gilles FH, Sugita K, Abe S, Sako M, Hashizume K, Hayashi Y.

Genes Chromosomes Cancer. 2002 May;34(1):33-41.

PMID:
11921280
18.

Highly aggressive behavior of malignant rhabdoid tumor: a special reference to SMARCB1/INI1 gene alterations using molecular genetic analysis including quantitative real-time PCR.

Kohashi K, Oda Y, Yamamoto H, Tamiya S, Izumi T, Ohta S, Taguchi T, Suita S, Tsuneyoshi M.

J Cancer Res Clin Oncol. 2007 Nov;133(11):817-24. Epub 2007 May 8.

PMID:
17486366
19.

Heterozygosity loss at 22q and lack of INI1 gene mutation in gastrointestinal stromal tumor.

Yamamoto H, Kohashi K, Tsuneyoshi M, Oda Y.

Pathobiology. 2011;78(3):132-9. doi: 10.1159/000323564. Epub 2011 May 26.

PMID:
21613800
20.

Indications for a tumor suppressor gene at 22q11 involved in the pathogenesis of ependymal tumors and distinct from hSNF5/INI1.

Kraus JA, de Millas W, Sörensen N, Herbold C, Schichor C, Tonn JC, Wiestler OD, von Deimling A, Pietsch T.

Acta Neuropathol. 2001 Jul;102(1):69-74.

PMID:
11547953

Supplemental Content

Support Center